SANUWAVE Health Inc

SANUWAVE Health Inc operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 13.56, indicating significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.38, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of $10.97 million supports operational flexibility, though the negative net cash position after subtracting total debt raises concerns about long-term liquidity. Profitability metrics show mixed performance. The company reports a net income of $11.81 million and a return on equity of 7.30%, but its return on assets of 0.32% is significantly below industry norms, indicating inefficient asset utilization. Gross profit of $33.97 million represents 77.1% of revenue, suggesting strong cost control in production, though operating income of $4.27 million reflects higher overhead costs. Geographic and segment exposure is not disclosed in the available data, but the company's revenue concentration in a single product line (wound care devices) introduces operational risk. The absence of segment-specific revenue breakdowns limits visibility into diversification efforts. Growth trajectory is constrained by the company's current financial position. While revenue of $44.05 million is reported, no specific growth rate is provided. Analysts project a mean price target of $43.50, implying a 156% upside from the current market price of $16.96, though this is based on limited data and no recent revenue growth figures. Risk factors include high leverage and potential dilution, though the latter is assessed as low. The company's negative net cash position after debt subtraction raises liquidity concerns, and the absence of disclosed capital expenditure plans beyond the $1.94 million outflow suggests limited investment in future growth. Recent events include the publication of the latest financial data in the HA-latest source, but no specific filings or transcripts are cited in the available data. The company's reliance on a single product line and high debt levels remain key operational risks.